Abstract
Objective and background: Her-2/neu tyrosine kinase has been implicated in the development and progression of several human cancers and is target for therapeutic intervention. Smaller studies suggest that Her-2/neu may be involved in the tumerogenesis of endometrial adenocarcinoma. The aim of this study was to evaluate Her-2/neu expression in endometrial carcinoma (EC) and its correlation with clinicopathological features in order to define the potential prognostic value of Her-2/neu overexpression in EC. Patients and methods: Nineteen patients with stage I-IV EC were included in this study. Demographic, clinical and pathologic information was obtained and recorded. Her-2/neu expression was evaluated by immunohistochemistry (IHC) on paraffin embedded tissue sections with Her-2/neu antibody. Overexpression was defined as complete membrane staining in greater than 10% of cells. Results: The positive rate of Her-2/neu in EC was 42.1%. Her-2/neu was associated with surgical stage (p 0.05). Conclusion: Our study provides evidence of Her-2/neu overexpression in a considerable proportion of the patients with uterine adenocarcinoma, thus suggesting the opportunity for the possible use of anti-Her-2/neu therapy in this malignancy by selective inhibition of Her-2/neu. The use of Herceptin, a monoclonal antibody directed against Her-2/neu, for therapy of patients harboring Her-2/neu positive EC may be beneficial. Her-2/neu overexpression is related to most of the prognostic variables of EC and may be incorporated into the criteria for determination of tumor aggressiveness as a prognostic marker.
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
